First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment.

Détails

Ressource 1Télécharger: 27927678_BIB_E4AC4FB222A2.pdf (480.77 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_E4AC4FB222A2
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment.
Périodique
The British journal of ophthalmology
Auteur(s)
Munier F.L., Mosimann P., Puccinelli F., Gaillard M.C., Stathopoulos C., Houghton S., Bergin C., Beck-Popovic M.
ISSN
1468-2079 (Electronic)
ISSN-L
0007-1161
Statut éditorial
Publié
Date de publication
08/2017
Peer-reviewed
Oui
Volume
101
Numéro
8
Pages
1086-1093
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article
Publication Status: ppublish
Résumé
The introduction of intra-arterial chemotherapy (IAC) as salvage treatment has improved the prognosis for eye conservation in group D retinoblastoma. The aim of this study was to compare the outcomes of consecutive patients with advanced unilateral disease treated with either first-line intravenous chemotherapy (IVC) or first-line IAC.
This is a retrospective mono-centric comparative review of consecutive patients.
Sporadic unilateral retinoblastoma group D cases treated conservatively at Jules-Gonin Eye Hospital and CHUV between 1997 and 2014. From January 1997 to August 2008, IVC, combined with focal treatments, was the primary treatment approach. From September 2008 to October 2014, IAC replaced IVC as first-line therapy.
48 patients met the inclusion criteria, receiving only either IAC or IVC as primary treatment modality.
Outcomes of 23 patients treated by IVC were compared with those of 25 treated by IAC; mean follow-up was 105.3 months (range 29.2-218.6) and 41.7 months (range 19.6-89.5), respectively. Treatment duration was significantly shorter in the IAC group (p<0.001). Ten eyes in the IVC group underwent enucleation. Recordable visual acuity of the salvaged eyes was significantly better in the IAC group (0.9 vs 1.4 logarithm of the minimum angle of resolution, p<0.01). No extraocular disease, metastases or long-term systemic complications were observed in either group.
The difference in the time frame between treatment groups had an impact on the availability of intravitreal chemotherapy treatment. Despite this, the results reported here imply that eyes treated with first-line IAC will have shorter treatment period, better ocular survival and visual acuity than first-line IVC.

Mots-clé
Aftercare, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Carboplatin/administration & dosage, Child, Child, Preschool, Etoposide/administration & dosage, Humans, Infant, Infusions, Intra-Arterial, Infusions, Intravenous, Melphalan/administration & dosage, Retinal Neoplasms/drug therapy, Retinoblastoma/drug therapy, Retrospective Studies, Salvage Therapy/methods, Treatment Outcome, Vision Disorders/prevention & control, Child health (paediatrics), Neoplasia, Retina, Treatment Medical
Pubmed
Web of science
Open Access
Oui
Création de la notice
09/12/2016 15:24
Dernière modification de la notice
20/08/2019 16:08
Données d'usage